Anti-inflammatories
This article was originally published in The Tan Sheet
Executive Summary
Active recruitment for Alzheimer's Disease Anti-inflammatory Prevention Trial began Jan. 30; target enrollment is 2,625 adults over age 70. The National Institute on Aging-sponsored trial will compare effects of Bayer's Aleve (naproxen sodium), Searle/Pfizer's Rx COX-2 Celebrex (celecoxib) and placebo on age-related memory loss among healthy participants with a family history of dementia or Alzheimer's. The four-center, seven-year trial headed by John Breitner, MD, Johns Hopkins School of Hygiene & Public Health, resembles another NIA trial investigating effects of Merck's Vioxx and Aleve on cognitive decline in Alzheimer's patients; the latter trial hopes to produce results by 2002 (1"The Tan Sheet" Feb. 21, 2000, p. 13)